WHO Goes Against Gilead’s Remdesivir as the Drug Shows No Sign of Improving Survivability

WHO advised against Gilead’s remdesivir for coronavirus treatment as the drug shows no evidence in improving survival rates or the need for ventilation.

 

On Friday, the World Health Organization (WHO) Guideline Development Group published their findings in the British medical trade journal (BMJ), saying that the drug has no meaningful effect on mortality or on other important outcomes for patients, such as the need for mechanical ventilation or time to clinical improvement.

The organization backed up its claim after four randomized trials involving more than 7,000 hospitalized coronavirus patients.

 

The share price of Gilead Sciences Inc. fell in after-hours trading, dropping 1.62% to $59.65 per share.